Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd.

TTPEX:6576
70.60
TWD
-0.90
(-1.26%)
0.14EPS
561.91P/E
12.73BMarket Cap
Foresee Pharmaceuticals Co., Ltd.
TPEX:6576
(Taipei Exchange)

Recent

price

70.60

P/E

ratio

561.91

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
- -
0.29
0.3
0.78
2.25
1.9
2.55
1.53
3.05
2.78
3.01
Revenue per Share
-4.93
-5.76
-4.12
-5.41
-6.37
-5.02
-4.98
-4.8
-4
-8.14
-7.87
-5.7
0.14
Basic EPS, GAAP
54.91
-8.38
-3.75
-6.67
-6.61
-6.39
-6.85
-1.86
-2.47
-7.34
-9.68
-5.54
-3.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.6
4.91
7.08
7.2
5.39
8.69
15.47
11.07
7.62
9.16
10.33
5.9
8.08
Book Value per Share
0.6
4.25
6.54
6.11
3.49
6.33
13.7
9.77
6.44
8.23
9.57
5.2
7.43
Tangible Book Value per Share
2
57
75
82
87
97
103
119
118
127
137
155
156
Basic Weighted Avg Shares
- -
- -
- -
24
26
75
230
226
302
195
419
431
471
Sales/Revenue/Turnover
- -
- -
- -
-1,867.17
-2,093.26
-625.18
-210.38
-238.3
-155.7
-516.63
-257.9
-199.95
-104.5
Operating Margin (%)
1
6
9
13
17
39
49
51
51
74
81
68
56
Depreciation Expense
-8
-331
-309
-443
-552
-487
-511
-569
-473
-1,036
-1,081
-883
22
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
74.79
Effective Tax Rate (%)
- -
- -
- -
-1,869.28
-2,118.28
-647.91
-221.63
-251.86
-156.76
-531.33
-258.2
-204.78
4.77
Profit Margin (%)
32
289
407
480
194
489
1,565
1,229
786
1,120
1,424
699
1,028
Working Capital
- -
- -
- -
- -
- -
3
70
6
26
13
93
21
384
LT Debt
42
345
539
604
499
896
1,829
1,320
911
1,245
1,599
930
1,273
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8.52
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.7
Return on Capital (%)
- -
-170.72
-69.76
-77.6
-100.07
-69.88
-37.48
-36.15
-42.37
-96.17
-76.04
-69.85
2
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
211
14
14
LT Borrowings
- -
368
371
LT Finance Leases
21
17
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
158
158
158
Market Capitalization
12,698
12,068
12,729

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
986
1,225
1,157
Cash, Cash Equivalents & STI
700
892
911
Accounts Receivable, Net
43
81
56
Inventories
145
140
163
Total Current Liabilities
286
90
129
Payables & Accruals
- -
- -
- -
ST Debt
211
14
14
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.91%
-7.11%
-41.86%
Free Cash Flow
27.01%
38.15%
-35.49%
Net Income, GAAP
15.43%
19.95%
-18.31%
Sales/Revenue/Turnover
- -
22.77%
3.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
104
94
80
141
419
2025
110
112
157
52
431
2026
80
182
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.88
-1.21
-2.25
-3.52
-7.87
2025
-1.9
-2.14
-0.74
-0.93
-5.7
2026
2.59
-0.79
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576) develops and commercializes biopharmaceutical products focused on stabilized injectable formulation (SIF) long-acting injectable technologies and novel chemical entity (NCE) programs targeting specialty markets, rare diseases, oncology, respiratory disorders, neurology, and high unmet medical needs; its core SIF pipeline includes CAMCEVI (leuprolide mesylate, FP-001) 42 mg and 21 mg approved in the US, Canada, and EU for advanced prostate cancer and launched in the US, with ongoing Phase 3 trials for central precocious puberty and premenopausal breast cancer, FP-014 (triptorelin) in Phase 3 for prostate cancer, FP-016 and FP-017 (undisclosed) for neurology/psychiatry; its NCE portfolio features Aderamastat (FP-025, MMP-12 inhibitor) with Phase 2 proof-of-concept in allergic asthma completed positively and planned for cardiac sarcoidosis, Linvemastat (FP-020, MMP-12 inhibitor) in Phase 2 for asthma/COPD and inflammatory bowel disease, Mirivadelgat (FP-045, ALDH2 activator) in Phase 2 for pulmonary hypertension associated with interstitial lung disease, alongside earlier-stage MMP-12 inhibitors for idiopathic pulmonary fibrosis and neurology, and ALDH2 activators for cardiovascular, renal, metabolic diseases, and neurology. Founded in 2013 and headquartered in Taipei, Taiwan, with US operations, the company conducts R&D and clinical activities in the United States, China, and Europe, serving endocrinology, oncology, respiratory, and rare disease patient populations through proprietary SIF-ADAGIO, SIF-LEGATO, SIF-DUO, and SIF-MEZZO platforms. Recent developments include the completion of a US$42.1 million public financing in December 2024 to advance FP-014 Phase 3 trials, FP-020 Phase 2 studies in asthma and IBD, and FP-045 Phase 2 in PH-ILD; progression of CAMCEVI expansions and NCE programs such as FP-025 positive Phase 2 outcomes; and strategic partnerships including GeneScience Pharmaceuticals for CAMCEVI in China.